These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
131 related articles for article (PubMed ID: 9881102)
1. Antitumor agents. Part 186: Synthesis and biological evaluation of demethylcolchiceinamide analogues as cytotoxic DNA topoisomerase II inhibitors. Guan J; Zhu XK; Tachibana Y; Bastow KF; Brossi A; Hamel E; Lee KH Bioorg Med Chem; 1998 Nov; 6(11):2127-31. PubMed ID: 9881102 [TBL] [Abstract][Full Text] [Related]
2. Antitumor agents. 185. Synthesis and biological evaluation of tridemethylthiocolchicine analogues as novel topoisomerase II inhibitors. Guan J; Zhu XK; Tachibana Y; Bastow KF; Brossi A; Hamel E; Lee KH J Med Chem; 1998 May; 41(11):1956-61. PubMed ID: 9599244 [TBL] [Abstract][Full Text] [Related]
3. Synthesis of new 3-arylisoquinolinamines: effect on topoisomerase I inhibition and cytotoxicity. Cho WJ; Min SY; Le TN; Kim TS Bioorg Med Chem Lett; 2003 Dec; 13(24):4451-4. PubMed ID: 14643344 [TBL] [Abstract][Full Text] [Related]
4. Synthesis of 2-(thienyl-2-yl or -3-yl)-4-furyl-6-aryl pyridine derivatives and evaluation of their topoisomerase I and II inhibitory activity, cytotoxicity, and structure-activity relationship. Thapa P; Karki R; Choi H; Choi JH; Yun M; Jeong BS; Jung MJ; Nam JM; Na Y; Cho WJ; Kwon Y; Lee ES Bioorg Med Chem; 2010 Mar; 18(6):2245-2254. PubMed ID: 20188578 [TBL] [Abstract][Full Text] [Related]
5. Bis(phenazine-1-carboxamides): structure-activity relationships for a new class of dual topoisomerase I/II-directed anticancer drugs. Spicer JA; Gamage SA; Rewcastle GW; Finlay GJ; Bridewell DJ; Baguley BC; Denny WA J Med Chem; 2000 Apr; 43(7):1350-8. PubMed ID: 10753472 [TBL] [Abstract][Full Text] [Related]
6. Antitumor agents. Part 215: antitubulin effects of cytotoxic B-ring modified allocolchicinoids. Han S; Hamel E; Bastow KF; McPhail AT; Brossi A; Lee KH Bioorg Med Chem Lett; 2002 Oct; 12(20):2851-3. PubMed ID: 12270161 [TBL] [Abstract][Full Text] [Related]
7. Novel angular benzophenazines: dual topoisomerase I and topoisomerase II inhibitors as potential anticancer agents. Vicker N; Burgess L; Chuckowree IS; Dodd R; Folkes AJ; Hardick DJ; Hancox TC; Miller W; Milton J; Sohal S; Wang S; Wren SP; Charlton PA; Dangerfield W; Liddle C; Mistry P; Stewart AJ; Denny WA J Med Chem; 2002 Jan; 45(3):721-39. PubMed ID: 11806724 [TBL] [Abstract][Full Text] [Related]
8. Chalcones, inhibitors for topoisomerase I and cathepsin B and L, as potential anti-cancer agents. Kim SH; Lee E; Baek KH; Kwon HB; Woo H; Lee ES; Kwon Y; Na Y Bioorg Med Chem Lett; 2013 Jun; 23(11):3320-4. PubMed ID: 23608763 [TBL] [Abstract][Full Text] [Related]
9. Pyrimidoquinazoline-based antitumor agents. Design of topoisomerase II to DNA cross-linkers with activity against protein kinases. Skibo EB; Huang X; Martinez R; Lemus RH; Craigo WA; Dorr RT J Med Chem; 2002 Dec; 45(25):5543-55. PubMed ID: 12459022 [TBL] [Abstract][Full Text] [Related]
10. Synthesis and biological evaluation of novel anticancer bivalent colchicine-tubulizine hybrids. Malysheva YB; Combes S; Allegro D; Peyrot V; Knochel P; Gavryushin AE; Fedorov AY Bioorg Med Chem; 2012 Jul; 20(14):4271-8. PubMed ID: 22739088 [TBL] [Abstract][Full Text] [Related]
12. Mechanism of cytotoxicity of N-[2-(dimethylamino)ethyl] acridine-4-carboxamide and of its 7-chloro derivative: the roles of topoisomerases I and II. Bridewell DJ; Finlay GJ; Baguley BC Cancer Chemother Pharmacol; 1999; 43(4):302-8. PubMed ID: 10071981 [TBL] [Abstract][Full Text] [Related]
13. Synthesis and biological evaluation of tetrademethyl isocolchicine derivatives as inhibitors of DNA topoisomerase action in vitro. Bastow KF; Tatematsu H; Sun L; Fukushima Y; Lee KH Bioorg Med Chem; 1993 Sep; 1(3):227-34. PubMed ID: 8081856 [TBL] [Abstract][Full Text] [Related]
14. Substituted dibenzo[c,h]cinnolines: topoisomerase I-targeting anticancer agents. Yu Y; Singh SK; Liu A; Li TK; Liu LF; LaVoie EJ Bioorg Med Chem; 2003 Apr; 11(7):1475-91. PubMed ID: 12628673 [TBL] [Abstract][Full Text] [Related]
15. Synthesis and structure-activity relationship studies on tryprostatin A, an inhibitor of breast cancer resistance protein. Jain HD; Zhang C; Zhou S; Zhou H; Ma J; Liu X; Liao X; Deveau AM; Dieckhaus CM; Johnson MA; Smith KS; Macdonald TL; Kakeya H; Osada H; Cook JM Bioorg Med Chem; 2008 Apr; 16(8):4626-51. PubMed ID: 18321710 [TBL] [Abstract][Full Text] [Related]
16. L-proline analogues of anthraquinone-2-carboxylic acid: cytotoxic activity in breast cancer MCF-7 cells and inhibitory activity against topoisomerase I and II. Bielawska A; Kosk K; Bielawski K Pol J Pharmacol; 2001; 53(3):283-7. PubMed ID: 11785929 [TBL] [Abstract][Full Text] [Related]
17. Synthesis and pharmacological evaluation of novel bisindolylalkanes analogues. Song YL; Dong YF; Yang T; Zhang CC; Su LM; Huang X; Zhang DN; Yang GL; Liu YX Bioorg Med Chem; 2013 Dec; 21(24):7624-7. PubMed ID: 24262885 [TBL] [Abstract][Full Text] [Related]
18. Antitumor agents. 178. Synthesis and biological evaluation of substituted 2-aryl-1,8-naphthyridin-4(1H)-ones as antitumor agents that inhibit tubulin polymerization. Chen K; Kuo SC; Hsieh MC; Mauger A; Lin CM; Hamel E; Lee KH J Med Chem; 1997 Sep; 40(19):3049-56. PubMed ID: 9301667 [TBL] [Abstract][Full Text] [Related]
19. Design, synthesis and systematic evaluation of cytotoxic 3-heteroarylisoquinolinamines as topoisomerases inhibitors. My Van HT; Woo H; Jeong HM; Khadka DB; Yang SH; Zhao C; Jin Y; Lee ES; Youl Lee K; Kwon Y; Cho WJ Eur J Med Chem; 2014 Jul; 82():181-94. PubMed ID: 24904965 [TBL] [Abstract][Full Text] [Related]
20. Syntheses of novel antitumor dihydroxanthone derivatives with inhibitory activity against DNA topoisomerase II. Sato S; Suga Y; Yoshimura T; Nakagawa R; Tsuji T; Umemura K; Andoh T Bioorg Med Chem Lett; 1999 Sep; 9(18):2653-6. PubMed ID: 10509910 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]